Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata

August 2023 in “ International journal of research in dermatology ”

Andrea Sierra Franco, Paulina García de León Flores, Paula Alba, María Jimena Talamante Madrid, C. E. Calvo Rodríguez, Renata Monserrat Espejo Nuño

Janus kinase inhibitors JAKis alopecia areata tofacitinib ruxolitinib baricitinib JAK inhibitors AA

TLDR Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

The study reviewed literature from January 1, 2017, to April 16, 2023, on the efficacy and safety of Janus kinase inhibitors (JAKis) in treating adult patients with alopecia areata (AA). The findings indicate that oral JAKis, including tofacitinib, ruxolitinib, and baricitinib, are effective in reducing hair loss and are generally safe for use, even in severe cases of AA. The authors suggest that further research is needed to optimize dosage and treatment duration.

View this study on ijord.com →

Discuss this study in the Community →

9 / 9 results

research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?

June 2022 in “Frontiers in Immunology”

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib

1 citations , February 2022 in “JAAD case reports”

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , July 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

48 citations , February 2018 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata

30 citations , June 2017 in “Journal of cutaneous medicine and surgery”

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis

39 citations , April 2016 in “Case Reports in Dermatology”

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata

Related

research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?

research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib

research Efficacy of Systemic Minoxidil and Tofacitinib Combination in Treatment-Resistant Alopecia Universalis

research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata

research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis